Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals director Daphne Quimi received a stock option grant covering 24,372 shares of Common Stock. The option has an exercise price of $14.31 per share and expires on June 3, 2036. It vests in full on the earlier of June 4, 2027 or the next annual meeting, subject to her continuous service, and represents her entire reported option position in this filing.
Amylyx Pharmaceuticals director George M. Milne Jr. received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and expire on June 3, 2036. They vest in full on the earlier of June 4, 2027 or the next annual meeting, as long as he continues serving the company.
Amylyx Pharmaceuticals director Paul R. Fonteyne received a grant of stock options covering 24,372 shares of common stock. The options have an exercise price of $14.31 per share and were awarded at no cost to him as compensation.
These options vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, as long as he continues serving the company through that date. After this grant, he holds 24,372 stock options directly.
Amylyx Pharmaceuticals, Inc. reported the results of its annual stockholder meeting. Stockholders elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors to serve until the 2029 annual meeting, with each nominee receiving more than 76 million votes for.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 102,036,295 votes for and minimal opposition. In a non-binding advisory vote, stockholders approved the compensation of the company’s named executive officers, with 77,534,824 votes for and 13,490,653 against.
Amylyx Pharmaceuticals director Karen Firestone made an open-market purchase of the company’s Common Stock. On May 21, 2026, she bought 3,800 shares at a price of $13.51 per share. Following this transaction, she directly owns 66,900 shares of Amylyx common stock.
Amylyx Pharmaceuticals ownership update: Perceptive Life Sciences Master Fund, Ltd. directly holds 8,284,882 shares of Common Stock, representing 7.5% of the class based on 111,186,317 shares outstanding as of April 27, 2026. Perceptive Advisors LLC is the investment manager and Joseph Edelman is the managing member; all three Reporting Persons report shared voting and dispositive power over the same 8,284,882 shares.
Amylyx Pharmaceuticals reported a larger net loss while advancing its endocrine and neurodegenerative pipeline in the first quarter of 2026. The company posted a net loss of $41.3 million, or $0.37 per share, compared with a net loss of $35.9 million, or $0.42 per share, a year earlier.
Research and development expenses rose to $27.6 million, mainly from increased spending on avexitide for post-bariatric hypoglycemia and $4.0 million in milestone payments tied to AMX0318. Cash, cash equivalents, and short-term investments were $279.8 million at March 31, 2026, which the company expects to fund operations into 2028.
Amylyx completed enrollment in its 78-participant Phase 3 LUCIDITY trial of avexitide in PBH and expects topline data in the third quarter of 2026, with a potential commercial launch in 2027 if approved. The company is also progressing the AMX0114 ALS program and preclinical candidate AMX0318.
Amylyx Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 at 9:00 a.m. Eastern Time. The meeting will be held online via live webcast, allowing stockholders to vote and submit questions remotely.
Stockholders will vote on electing two Class II directors (George Mclean Milne Jr., Ph.D. and Paul Fonteyne) to terms ending in 2029, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The proxy describes a board dominated by independent directors, four standing committees, and an executive pay program emphasizing at-risk bonuses and equity, including one-time performance stock units tied to key avexitide Phase 3 and FDA approval milestones. It also notes Deloitte audit fees of $862,500 for 2025 and outlines policies on clawbacks, hedging, and board nomination and governance.